Guiding the Starting Dose of the Once-daily Formulation of Tacrolimus in " Adult Renal Transplant Patients: a Population Approach

Overview

Journal Front Pharmacol

Date 2024 Oct 4

PMID 39364055

Authors

Beatriz Fernandez-Alarcon

Oscar Nolberger

Anna Vidal-Alabro

Raul Rigo-Bonnin

Josep M Grinyo

Edoardo Melilli

Nuria Montero

Anna Manonelles

Ana Coloma

Alex Fava

Sergi Codina

Josep M Cruzado

Helena Colom

Nuria Lloberas

Affiliations

Soon will be listed here.

Abstract

Aims: The once-daily extended-release tacrolimus formulation (ER-Tac) has demonstrated similar efficacy and safety to the twice-daily immediate-release formulation (IR-Tac), but few population-based pharmacokinetic models have been developed in kidney transplant patients to optimize doses. Therefore, this study aimed i) at developing a population pharmacokinetic model for ER-Tac in adult kidney transplant patients ii) and identifying genetic factors and time-varying covariates predictive of pharmacokinetic variability to guide tacrolimus dosage during the early post-transplant period.

Methods: A total of 1,067 blood tacrolimus concentrations from 138 kidney transplant patients were analyzed. A total of 29 out of 138 patients were intensively sampled for 24 h on the day 5 post-transplantation; meanwhile, for the remaining patients, concentrations were collected on days 5, 10, and 15 after transplantation. Tacrolimus daily doses and genetic and demographic characteristics were retrieved from the medical files. Biochemistry time-varying covariates were obtained on different days over the pharmacokinetic (PK) study. A simultaneous PK analysis of all concentrations was carried out using the non-linear mixed-effects approach with NONMEM 7.5.

Results: A two-compartment model with linear elimination and delayed absorption best described the tacrolimus pharmacokinetics. Between-patient variability was associated with oral blood clearance (CL/F) and the central compartment distribution volume (Vc/F). Tacrolimus concentrations standardized to a hematocrit value of 45% significantly improved the model ( < 0.001). This method outperformed the standard covariate modeling of the hematocrit-blood clearance relationship. The effect of the CYP3A5 genotype was statistically ( < 0.001) and clinically significant on CL/F. The CL/F of patients who were CYP3A5 carriers was 51% higher than that of CYP3A5 non-carriers. Age also influenced CL/F variability ( < 0.001). Specifically, CL/F declined by 0.0562 units per each increased year from the value estimated in patients who were 60 years and younger.

Conclusion: The 36% between-patient variability in CL/F was explained by CYP3A5 genotype, age, and hematocrit. Hematocrit standardization to 45% explained the variability of tacrolimus whole-blood concentrations, and this was of utmost importance in order to better interpret whole-blood tacrolimus concentrations during therapeutic drug monitoring. The dose requirements of CYP3A5 carriers in patients aged 60 years or younger would be highest, while CYP3A5 non-carriers older than 60 years would require the lowest doses.

References

Kramer B, Charpentier B, Backman L, Tedesco Silva Jr H, Mondragon-Ramirez G, Cassuto-Viguier E . Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010; 10(12):2632-43. DOI: 10.1111/j.1600-6143.2010.03256.x. View

Holford N, Anderson B . Allometric size: The scientific theory and extension to normal fat mass. Eur J Pharm Sci. 2017; 109S:S59-S64. DOI: 10.1016/j.ejps.2017.05.056. View

Spagnoletti G, Gargiulo A, Salerno M, Favi E, Pedroso J, Calia R . Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. Transplant Proc. 2014; 46(7):2224-7. DOI: 10.1016/j.transproceed.2014.08.003. View

Zhao C, Jiao Z, Mao J, Qiu X . External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2015; 81(5):891-907. PMC: 4834594. DOI: 10.1111/bcp.12830. View

Saint-Marcoux F, Debord J, Undre N, Rousseau A, Marquet P . Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010; 32(2):129-35. DOI: 10.1097/FTD.0b013e3181cc70db. View

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

Zhang H, Li D, Zhu H, Fang Y, Liu T . Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017; 42(4):425-432. DOI: 10.1111/jcpt.12523. View

Savic R, Karlsson M . Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009; 11(3):558-69. PMC: 2758126. DOI: 10.1208/s12248-009-9133-0. View

Storset E, Holford N, Hennig S, Bergmann T, Bergan S, Bremer S . Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014; 78(3):509-23. PMC: 4243902. DOI: 10.1111/bcp.12361. View

10.

Anderson B, Holford N . Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009; 24(1):25-36. DOI: 10.2133/dmpk.24.25. View

11.

Storset E, Holford N, Midtvedt K, Bremer S, Bergan S, Asberg A . Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2013; 70(1):65-77. PMC: 3889505. DOI: 10.1007/s00228-013-1584-7. View

12.

Kirubakaran R, Stocker S, Hennig S, Day R, Carland J . Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. Clin Pharmacokinet. 2020; 59(11):1357-1392. DOI: 10.1007/s40262-020-00922-x. View

13.

Campagne O, Mager D, Tornatore K . Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. J Clin Pharmacol. 2018; 59(3):309-325. PMC: 7395655. DOI: 10.1002/jcph.1325. View

14.

Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V . Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995; 29(6):404-30. DOI: 10.2165/00003088-199529060-00003. View

15.

Lu Z, Bonate P, Keirns J . Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. Br J Clin Pharmacol. 2019; 85(8):1692-1703. PMC: 6624387. DOI: 10.1111/bcp.13952. View

16.

Andrews L, de Winter B, van Gelder T, Hesselink D . Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. Pharmacogenomics. 2016; 17(16):1737-1740. DOI: 10.2217/pgs-2016-0136. View

17.

Zhao W, Fakhoury M, Baudouin V, Storme T, Maisin A, Deschenes G . Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2012; 69(2):189-95. DOI: 10.1007/s00228-012-1330-6. View

18.

Bergmann T, Hennig S, Barraclough K, Isbel N, Staatz C . Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2013; 36(1):62-70. DOI: 10.1097/FTD.0b013e31829f1ab8. View

19.

Abrantes J, Jonsson S, Karlsson M, Nielsen E . Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019; 85(6):1326-1336. PMC: 6533430. DOI: 10.1111/bcp.13901. View

20.

Wlodarczyk Z, Squifflet J, Ostrowski M, Rigotti P, Stefoni S, Citterio F . Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009; 9(11):2505-13. DOI: 10.1111/j.1600-6143.2009.02794.x. View